Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant study
Question
Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant study
Direct answer
A 77% overall response rate in first-line HNSCC creates a clinical foundation for regulatory label expansion, expanding the addressable patient base for J&J's Rybrevant oncology franchise. — bullish pressure on JNJ via oncology franchise expansion via Phase 1b/2 frontline head and neck response data.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-26
- Published
- 2026-10-26
- Revision
- 1 · 2026-10-27
Cite as: Market Ontology, “Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant study”, revision 1, evidence through 2026-10-26. https://marketontology.com/catalysts/2026-10-26/johnson-johnson-reports-77-response-rate-in-phase-1b-2-rybrevant-study-fb4182
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| JNJ | ▲Bull | 1–4 weeks | oncology franchise expansion via Phase 1b/2 frontline head and neck response data | 77 |
Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant study
A 77% overall response rate in first-line HNSCC creates a clinical foundation for regulatory label expansion, expanding the addressable patient base for J&J's Rybrevant oncology franchise. — bullish pressure on JNJ via oncology franchise expansion via Phase 1b/2 frontline head and neck response data.
Subcutaneous amivantamab combination achieved a 77% overall response rate in the OrigAMI-4 trial.
- SourceSubcutaneous amivantamab combination achieved a 77% overall response rate in the OrigAMI-4 trial.
- TransmissionA 77% overall response rate in first-line HNSCC creates a clinical foundation for regulatory label expansion, expanding the addressable patient base for J&J's Rybrevant oncology franchise.
- SummaryJohnson & Johnson reported a 77% overall response rate in the Phase 1b/2 OrigAMI-4 trial. The regimen tested subcutaneous amivantamab with pembrolizumab and carboplatin in head and neck cancer. Results show strong activity in first-line non-HPV head and neck squamous cell carcinoma.
- JNJDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Fed officials or competing data may reframe the print
- JNJ closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- JNJ price vs. pre-event level
- JNJ volume vs. 20-day average
- 2Y/10Y Treasury yield direction
- DXY direction
- Fed funds futures repricing
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| JNJ | Bullish | 266.30 2026-10-26 | Pending | Pending | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Subcutaneous RYBREVANT (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer · press_release · 2026-10-25
Related catalysts
- 2026-10-27Bristol Myers reports positive Phase 3 data on iza-brenBMY JNJ
- 2026-10-26Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancerJNJ MRK+0.86%
- 2026-10-26Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant studyJNJ
- 2026-10-26Johnson & Johnson Subcutaneous Amivantamab Hits 77% Response Rate in Head and Neck StudyJNJ
- 2026-10-26Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancerJNJ
- 2026-10-26Johnson & Johnson Reports 77% Response Rate in OrigAMI-4 Head and Neck Cancer TrialJNJ
- 2026-10-26Johnson & Johnson Subcutaneous Amivantamab Hits 77% Response Rate in Head and Neck StudyJNJ
- 2026-10-26J&J Reports 77% Response Rate in Phase 1b/2 Trial for Subcutaneous AmivantamabJNJ MRK+0.86%
Find trades for this development
Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.
First 10 runs free
See today's live cards
Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.